RP
SUPN icon

Raiff Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Raiff Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-15,000
Closed -$181K – 48
2015
Q1 		$181K Buy
+15,000
New +$142K 0.17% 37

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

Raiff Partners's SUPN Position: Q2 2015 in Review

Raiff Partners sold out of Supernus Pharmaceuticals (SUPN) in Q2 2015, closing a stake of 15,000 shares — an estimated $181K sold.

Raiff Partners first reported a position in SUPN in Q1 2015 and held it in 1 quarter. The position peaked at $181K in Q1 2015. 165 funds tracked by Wall St. Rank hold SUPN as of Q2 2015.

  • Raiff Partners reported no remaining Supernus Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Raiff Partners sold 15,000 Supernus Pharmaceuticals shares in Q2 2015, an estimated $181K.
  • Raiff Partners first reported a position in Supernus Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Raiff Partners's Supernus Pharmaceuticals position peaked at $181K in Q1 2015.
  • 165 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2015.

Based on Raiff Partners's 13F filing for Q2 2015, filed 13 Aug 2015.